CYTK
Price
$33.18
Change
-$0.73 (-2.15%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
3.96B
34 days until earnings call
NXTC
Price
$0.46
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
12.82M
33 days until earnings call
Interact to see
Advertisement

CYTK vs NXTC

Header iconCYTK vs NXTC Comparison
Open Charts CYTK vs NXTCBanner chart's image
Cytokinetics
Price$33.18
Change-$0.73 (-2.15%)
Volume$124.64K
Capitalization3.96B
NextCure
Price$0.46
Change-$0.00 (-0.00%)
Volume$175.86K
Capitalization12.82M
CYTK vs NXTC Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. NXTC commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and NXTC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (CYTK: $33.16 vs. NXTC: $0.46)
Brand notoriety: CYTK and NXTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 125% vs. NXTC: 71%
Market capitalization -- CYTK: $3.96B vs. NXTC: $12.82M
CYTK [@Biotechnology] is valued at $3.96B. NXTC’s [@Biotechnology] market capitalization is $12.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than NXTC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while NXTC’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 2 bearish.
  • NXTC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than NXTC.

Price Growth

CYTK (@Biotechnology) experienced а +2.25% price change this week, while NXTC (@Biotechnology) price change was -2.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

NXTC is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($3.96B) has a higher market cap than NXTC($12.8M). CYTK YTD gains are higher at: -29.507 vs. NXTC (-40.700). NXTC has higher annual earnings (EBITDA): -50.34M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. NXTC (55.9M). NXTC has less debt than CYTK: NXTC (4.91M) vs CYTK (791M). CYTK has higher revenues than NXTC: CYTK (19.2M) vs NXTC (0).
CYTKNXTCCYTK / NXTC
Capitalization3.96B12.8M30,938%
EBITDA-513.62M-50.34M1,020%
Gain YTD-29.507-40.70072%
P/E RatioN/AN/A-
Revenue19.2M0-
Total Cash938M55.9M1,678%
Total Debt791M4.91M16,100%
FUNDAMENTALS RATINGS
CYTK vs NXTC: Fundamental Ratings
CYTK
NXTC
OUTLOOK RATING
1..100
145
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6488
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (13) in the Biotechnology industry is significantly better than the same rating for CYTK (100). This means that NXTC’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as NXTC (100). This means that CYTK’s stock grew similarly to NXTC’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as NXTC (100). This means that CYTK’s stock grew similarly to NXTC’s over the last 12 months.

CYTK's Price Growth Rating (64) in the Biotechnology industry is in the same range as NXTC (88). This means that CYTK’s stock grew similarly to NXTC’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for NXTC (100). This means that CYTK’s stock grew significantly faster than NXTC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKNXTC
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
78%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IJUL31.800.21
+0.65%
Innovator Intl Dev Pwr Bffr ETF July
AIQ43.37-0.06
-0.14%
Global X Artfcl Intlgc & Tech ETF
SCHQ31.60-0.18
-0.57%
Schwab Long-Term US Treasury ETF
EMTY12.52-0.07
-0.58%
ProShares Decline of the Retl Store ETF
GNT6.21-0.11
-1.74%
GAMCO Natural Resources Gold & Income Trust

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IMVT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-2.21%
IMVT - CYTK
48%
Loosely correlated
-1.77%
IDYA - CYTK
48%
Loosely correlated
-4.04%
KRYS - CYTK
46%
Loosely correlated
-2.60%
ROIV - CYTK
44%
Loosely correlated
-1.81%
ACLX - CYTK
44%
Loosely correlated
+0.90%
More